Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Additive Benefits of Semaglutide for Open-AngLe Glaucoma - an Opportunity for Neuroprotection

NCT06792422 is registered in ClinicalTrials.gov with Glostrup University Hospital, Copenhagen as lead sponsor.

NCT NCT06792422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06792422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Additive Benefits of Semaglutide for Open-AngLe Glaucoma - an Opportunity for Neuroprotection
Lead sponsor
Glostrup University Hospital, Copenhagen
Phase
Phase 4
Overall status
Recruiting
Start date
January 31, 2025
Completion date
December 31, 2028
Enrollment
126 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, open-angle glaucoma, primary open angle glaucoma (poag)